Cocaine Dependence
187
5
6
148
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
88 trials with published results (47%)
Research Maturity
148 completed trials (79% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.0%
13 terminated out of 187 trials
91.9%
+5.4% vs benchmark
7%
13 trials in Phase 3/4
59%
88 of 148 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 148 completed trials
Clinical Trials (187)
Low-Intensity Focused Ultrasound for Cocaine Use Disorder
Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
Rebalancing the Serotonergic System in Cocaine Dependence
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
rTMS for Stimulant Use Disorders
Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use
Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction
TDCS for Cocaine Addiction Craving
TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET
Clavulanic Acid for the Treatment of Cocaine Use Disorder
Investigation of Cocaine Addiction Using mGluR5 PET and fMRI
Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder
Substance Abuse Pre-Treatment Screening Study
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid